Laurus Labs Shares in Focus As Q4 PAT Surges 148%

Synopsis:- Executing a sharp recovery from two years of earnings compression, Laurus Labs reported consolidated revenue of Rs.6,813 crore for FY26 up 23 percent year-on-year with net profit attributable to equity holders surging 148 percent to Rs.889 crore, backed by stronger API volumes, improving CDMO traction, and a near-tripling of operating cash flow to Rs.1,624 crore.

Shares of a Hyderabad-based pharma and biotech company surged into investor focus on April 30, 2026, as it announced results that confirmed a broad-based turnaround across its business segments. The FY26 performance stands in sharp contrast to the prior two years, when revenue stagnated and profit collapsed from the highs of FY22-23.

With a market capitalization of Rs. 59,732.43 crore, the shares of Laurus Labs Ltd were trading at Rs. 1,106.45 per share, up 0.03 percent from its previous closing price of Rs. 1,106.1. It is trading at a P/E of 70.93.

Consolidated revenue from operations for FY26 came in at Rs.6,812.90 crore, up 22.7 percent from Rs.5,553.96 crore in FY25. Consolidated profit before tax rose from Rs.484.29 crore to Rs.1,181.88 crore, while net profit attributable to equity holders reached Rs.888.79 crore, a 148 percent increase from Rs.358.32 crore.

Consolidated EPS (basic) jumped to Rs.16.47 from Rs.6.65 in FY25. The standalone performance was equally impressive: revenue grew to Rs.6,089.07 crore (up 17 percent) and PAT expanded from Rs.380.39 crore to Rs.740.48 crore. The board approved a second interim dividend of Rs.1.20 per equity share, with a record date of May 8, 2026.

The quality of earnings improved materially. Consolidated operating cash flow in FY26 was Rs.1,623.50 crore, nearly 2.7 times the Rs.601.65 crore generated in FY25. This freed up capital for both capacity investment and debt reduction; consolidated finance costs fell from Rs.216 crore in FY25 to Rs.170.73 crore in FY26, even as the company continued capex at pace.

Capital work-in-progress on the consolidated balance sheet expanded from Rs.458.36 crore to Rs.773.28 crore, reflecting ongoing manufacturing investments. Q4 FY26 consolidated revenue was Rs.1,811.57 crore, up from Rs.1,720.30 crore in Q4 FY25 and broadly consistent with the trajectory seen through the year.

FY26 saw Laurus Labs make several strategic bets beyond its core API and CDMO operations. The company formalised a joint venture with KRKA Pharma Private Limited, investing Rs.49 crore for a 49 percent stake , a partnership aimed at the Indian formulations market given KRKA’s global generics credentials.

It also invested Rs.35 crore into Laurus Bio Private Limited, its biologics subsidiary, under a definitive agreement with Eight Roads Ventures and F-Prime Capital; this subsidiary now operates at a 78.34 percent holding by Laurus Labs, with the external investors providing both capital and strategic validation for the biosimilars buildout. A composite restructuring scheme , demerging identified assets of Laurus Synthesis Private Limited into Sriam Labs while merging the residual into Laurus Labs , has been filed with the NCLT Amaravati bench, with an appointed date of April 1, 2026, pending final approval.

Business Overview

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company based in Hyderabad. It is the world’s leading third-party supplier of antiretroviral APIs and holds one of India’s largest high-potency API manufacturing capacities. The group employs over 6,500 people, including 1,050-plus scientists, across more than 11 facilities approved by global regulators including the USFDA, WHO-Geneva, MHRA, and EMA.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Laurus Labs Shares in Focus As Q4 PAT Surges 148% appeared first on Trade Brains.